The FDA made a big reversal in its cyclosporiasis probe, but it still thinks iceberg lettuce is to blame

This is a trust shock, not a balance-sheet event. For WMT, the direct P&L hit is likely limited to small write-offs and added QA/traceability costs; the more material risk is basket mix, because consumers tend to extrapolate one salad-kit issue into the broader bagged-produce aisle. That usually shows up as a short, sharp category air pocket rather than a durable demand problem unless the story keeps cycling in the press.

The second-order loser is any operator with high fresh-produce throughput and limited menu flexibility: QSR salad items, salad chains, and refrigerated prepared-food suppliers. The lingering investigation matters more than the original false-positive because unresolved traceback keeps the headline alive and extends consumer caution beyond the product shelf life. If the agency widens the scope to another ingredient or vendor, the event shifts from a supplier issue to an industry hygiene scare.

Contrarian view: the market may be overpricing duration. Food-safety headlines usually fade faster than earnings impacts, and WMT’s scale gives it the ability to absorb remediation without a meaningful margin reset. The key watchpoint is whether alternative ingredients or additional retailers get pulled in over the next 2-4 weeks; absent that, any WMT weakness should mean-revert as consumers normalize. The thesis breaks if FDA broadens the traceback or if produce sales remain soft into the next monthly comp cycle.